Welcome to our dedicated page for NextCure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on NextCure stock.
NextCure, Inc. (Nasdaq: NXTC) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel immunomedicines aimed at treating cancer and other immune-related diseases by restoring normal immune function. The company’s leading product candidate, NC318, is currently in Phase 2 clinical trials for advanced or metastatic solid tumors. NextCure is also advancing NC410, a novel immunomedicine designed to block immune suppression mediated by the immune modulator LAIR-1, and LNCB74, an ADC targeting B7-H4, a clinically validated cancer target. The company's pipeline includes additional antibodies in preclinical development targeting novel immune modulators expressed in inflamed tissue and tumor microenvironments across various cancer types.
NextCure has established significant partnerships including a license agreement with Yale University and a research collaboration with LigaChem Biosciences. Recent updates in their clinical pipeline include promising preclinical data on NC605 for preventing bone loss in patients with severe spinal cord injuries and the publication of a manuscript on the FLRT3-UNC5B pathway as a novel T cell checkpoint in cancer immunotherapy. Their innovative FIND-IO platform continues to discover new immunomedicine targets, expanding their therapeutic potential beyond oncology to chronic inflammatory diseases like COPD.
Financially, NextCure has a solid runway extending into the second half of 2026, focusing resources on high-priority programs such as NC410 in combination therapies and LNCB74, while seeking partners for other clinical and preclinical assets. The company's goal is to address unmet medical needs by providing new treatments for patients who do not respond to existing therapies or experience disease progression, leveraging scientific insights into biological pathways, cell interactions, and tumor microenvironments.
For the latest updates, visit www.nextcure.com
NextCure (NASDAQ: NXTC) reported its first quarter 2022 financial results, revealing a cash position of $201.3 million expected to fund operations into Q1 2024. The company is advancing its pipeline with updates anticipated for NC318, NC410, and NC762 in the second half of 2022, alongside an IND filing for NC525. However, the company faced a net loss of $20.6 million, increased R&D expenses of $15.0 million, and a decrease in cash from $219.6 million at the end of 2021.
NextCure, a clinical-stage biopharmaceutical company, announced its participation in the BofA Securities 2022 Healthcare Conference in Las Vegas on May 10 at 10:40 am PT. The event will feature a fireside chat accessible via a live audio webcast on the company's website, with a replay available for 30 days post-event. NextCure focuses on developing first-in-class immunomedicines targeting cancer and immune-related diseases, utilizing its proprietary FIND-IO™ platform to identify novel targets for new treatments.
NextCure, Inc. (Nasdaq: NXTC) announced the publication of a paper in the Journal of Clinical Investigation detailing a preclinical study on the tumor microenvironment's role in cancer treatment. The study, in collaboration with the National Cancer Institute, demonstrated that targeting collagens via LAIR-1 and TGF-β signaling improved immune activation in murine models, resulting in high cure rates for colon and mammary carcinoma. CEO Sol Langermann emphasized the superior results achieved by combining interventions, highlighting the potential of their immunomedicine NC410 to treat multiple cancer types.
NextCure, a clinical-stage biopharmaceutical company (Nasdaq: NXTC), will present at the 21st Annual Needham Virtual Healthcare Conference on April 12 at 3 pm ET. The event will be accessible via a live audio webcast on their website, with a replay available for 30 days. NextCure focuses on developing first-in-class immunomedicines targeting cancer and immune-related diseases through its FIND-IO platform.
They aim to provide new treatment options for patients unresponsive to current therapies.
NextCure, Inc. (Nasdaq: NXTC) reported its financial results for Q4 and FY 2021, ending with a cash position of $219.6 million expected to fund operations into Q1 2024. The company aims for multiple data readouts in 2022 for its clinical programs: NC318, NC410, and NC762. Notably, NC318 showed potential benefits in patients with various cancers. The company faced operational delays due to COVID-19 but anticipates updates on its programs later this year.
NextCure, Inc. (Nasdaq: NXTC) announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 10:40 am ET. The conference will provide insights into the company's innovative treatments for cancer and immune-related diseases using their FIND-IO™ platform.
Additionally, a live audio webcast will be available on NextCure's website, with a replay accessible for 30 days post-event.
NextCure, Inc. (Nasdaq: NXTC) announced promising preclinical data on novel immunomedicines targeting Siglec-15 and LAIR-1 for leukemia treatment at the American Society of Hematology annual meeting. These findings suggest that targeting S15 can activate T lymphocytes to combat aggressive pediatric B-ALL and that a new LAIR-1 monoclonal antibody effectively targets and kills leukemia stem cells in AML. The company is advancing ongoing clinical evaluations of NC318, NC410, and NC762 for solid tumors while focusing on solutions for patients unresponsive to current therapies.
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company focused on innovative immunotherapies, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 7, 2021, at 11:40 am ET. Investors can access the live audio webcast through the company’s website, with a replay available for 30 days post-event. NextCure aims to develop first-in-class immunomedicines targeting cancer and immune-related diseases, using its proprietary FIND-IO™ platform to explore various immune cell types.
NextCure, a clinical-stage biopharmaceutical company focused on immunomedicines for cancer and immune-related diseases, will participate in the Piper Sandler Virtual 32nd Annual Healthcare Conference on November 30. An audio webcast of the fireside chat will be available on the company’s website starting at 10 a.m. ET and archived for 30 days. NextCure utilizes its proprietary FIND-IO™ platform to discover novel immunomedicines targeting patients who do not respond to existing cancer therapies.
NextCure, Inc. (Nasdaq: NXTC) presented promising new data on its immunomedicines NC318 and NC410 at the Society for Immunotherapy of Cancer meeting. NC318, targeting Siglec-15, showed a 37% disease control rate and a median progression-free survival of 5.0 months in advanced solid tumors. Interim results for NC410 highlighted its safety and immune modulation potential with no dose-limiting toxicities. Collaborative non-clinical research indicated anti-tumor activity through immune system activation. NextCure aims to improve treatment options for cancer patients.
FAQ
What is the current stock price of NextCure (NXTC)?
What is the market cap of NextCure (NXTC)?
What is NextCure, Inc. known for?
What are the key products in development at NextCure?
What partnerships does NextCure have?
What is NC318?
How does NC410 work?
What recent achievements has NextCure made?
What is the FIND-IO platform?
What is LNCB74?
What is NextCure’s financial outlook?
Where can I find the latest updates on NextCure?
